<DOC>
	<DOC>NCT00673478</DOC>
	<brief_summary>The primary objective of this study is to characterize the pharmacokinetics (i.e. systemic exposure to tiotropium and salmeterol) of tiotropium qd + salmeterol qd or bid versus tiotropium qd and salmeterol bid following 4-week treatment periods in patients with chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Tiotropium and Salmeterol PK Study in COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>COPD patients of &gt;= 40 years old with moderate to severe COPD who are current or exsmokers with a smoking history of at least 10 packyears 1. Recent history of myocardial infarction, lifethreatening cardiac arrhythmia or hospitalisation for cardiac failure 2. History of asthma 3. Malignancy requiring treatment within past 5 years 4. Lifethreatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis 5. Known active tuberculosis 6. Pregnant or nusing women 7. Known hypersensitivity to components of the study medication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>